Answers are grounded in this paper and cite their sources.
INTRODUCTION: The rapid advancements in the management of inflammatory bowel disease (IBD) have given clinicians many new therapeutic options. The prevalence of IBD in the elderly is increasing, and the role of these therapeutic agents in the elderly population with IBD is still uncertain. AREAS COVERED: In this review, we will highlight the challenges facing clinicians managing IBD in the elderly, the considerations to take when starting new medications, when to consider for surgical referral, the potential pitfalls to avoid, and the non-pharmacological management measures that clinicians should be aware of. Expert Commentary: The safety of prescribing new IBD medications in elderly patients must be taken into consideration. Managing comorbidities, polypharmacy, functional status and drug interactions can also be challenging and requires an individualized approach.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: